LYNNETTE AVERILL to Hallucinogens
This is a "connection" page, showing publications LYNNETTE AVERILL has written about Hallucinogens.
Connection Strength
2.362
-
Open-label study of consecutive ibogaine and 5-MeO-DMT assisted-therapy for trauma-exposed male Special Operations Forces Veterans: prospective data from a clinical program in Mexico. Am J Drug Alcohol Abuse. 2023 09 03; 49(5):587-596.
Score: 0.802
-
Investigational drugs for assisting psychotherapy for posttraumatic stress disorder (PTSD): emerging approaches and shifting paradigms in the era of psychedelic medicine. Expert Opin Investig Drugs. 2022 02; 31(2):133-137.
Score: 0.721
-
Supportive Touch in Psychedelic Assisted Therapy. Am J Bioeth. 2025 Jan; 25(1):29-39.
Score: 0.220
-
Bio-Psycho-Spiritual Perspectives on Psychedelics: Clinical and Ethical Implications. Perspect Biol Med. 2024; 67(1):117-142.
Score: 0.205
-
Prospective associations of psychedelic treatment for co-occurring alcohol misuse and posttraumatic stress symptoms among United States Special Operations Forces Veterans. Mil Psychol. 2024 Mar-Apr; 36(2):184-191.
Score: 0.192
-
Policy considerations that support equitable access to responsible, accountable, safe, and ethical uses of psychedelic medicines. Neuropharmacology. 2022 11 15; 219:109214.
Score: 0.186
-
The effects of ketamine on prefrontal glutamate neurotransmission in healthy and depressed subjects. Neuropsychopharmacology. 2018 09; 43(10):2154-2160.
Score: 0.035